HRP20150062T1 - Farmaceutski pripravak koji sadrži optički aktivan spoj koji sadrži agonist receptora trombopoietina i njegov međuprodukt - Google Patents
Farmaceutski pripravak koji sadrži optički aktivan spoj koji sadrži agonist receptora trombopoietina i njegov međuprodukt Download PDFInfo
- Publication number
- HRP20150062T1 HRP20150062T1 HRP20150062AT HRP20150062T HRP20150062T1 HR P20150062 T1 HRP20150062 T1 HR P20150062T1 HR P20150062A T HRP20150062A T HR P20150062AT HR P20150062 T HRP20150062 T HR P20150062T HR P20150062 T1 HRP20150062 T1 HR P20150062T1
- Authority
- HR
- Croatia
- Prior art keywords
- ray
- crystal
- production
- pharmaceutical preparation
- solvate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 6
- 229940126460 thrombopoietin receptor agonist Drugs 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 238000002441 X-ray diffraction Methods 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000005260 alpha ray Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- YHVIKIKTANFPCN-UHFFFAOYSA-N 3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid Chemical compound CCOC(=O)C(C)=CC1=C(Cl)C=C(C(O)=O)C=C1Cl YHVIKIKTANFPCN-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- NOZIJMHMKORZBA-KJCUYJGMSA-N lusutrombopag Chemical compound CCCCCCO[C@@H](C)C1=CC=CC(C=2N=C(NC(=O)C=3C=C(Cl)C(\C=C(/C)C(O)=O)=C(Cl)C=3)SC=2)=C1OC NOZIJMHMKORZBA-KJCUYJGMSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Spoj naznačen time da je predstavljen s formulom:
[image]
njegova farmaceutski prihvatljiva sol, ili njegov solvat.
2. Spoj kako je definiran u zahtjevu 1, njegova farmaceutski prihvatljiva sol, ili njegov solvat naznačen time da je za uporabu kod profilakse ili liječenja trombocitopenije.
3. Farmaceutski pripravak naznačen time da sadrži, kao aktivni sastojak, optički aktivan spoj koji je predstavljen s formulom:
[image]
njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
4. Farmaceutski pripravak prema zahtjevu 3, naznačen time da je pripravak agonist receptora trombopoietina.
5. Farmaceutski pripravak prema zahtjevu 3, naznačen time da je pripravak sredstvo za regulaciju proizvodnje trombocita.
6. Kristal (S)-(E)-3-(2,6-dikloro-4-{4-[3-(1-heksiloksietil)-2-metiloksifenil]tiazol-2-ilkarbamoil}fenil)-2-metilakrilne kiseline naznačen time da ima glavni vršak kod difrakcije X-zraka na prahu s kutom difrakcije 2θ kod 17.8, 22.5, 23.3, i 24.4 stupnjeva, pri čemu su uvjeti mjerenja difrakcije X-zraka kako slijedi: vakuumska cijev CuK α-zraka, napon rendgenske cijevi 40kV, struja rendgenske cijevi 40mA ili 50mA.
7. Kristal prema zahtjevu 6 naznačen time da ima glavni vršak kod difrakcije X-zraka na prahu s kutom difrakcije 2θ kod 17.8, 21.1, 22.5, 23.3, 24.1 i 24.4 stupnjeva, pri čemu su X uvjeti mjerenja difrakcije X-zraka kao u zahtjevu 6.
8. Kristal kako je definiran u zahtjevu 6 ili 7 naznačen time da je za uporabu kod profilakse ili liječenja trombocitopenije.
9. Farmaceutski pripravak naznačen time da sadrži, kao aktivni sastojak, kristal kako je definiran u zahtjevu 6 ili 7.
10. Farmaceutski pripravak prema zahtjevu 9, naznačen time da je agonist receptora trombopoietina.
11. Farmaceutski pripravak prema zahtjevu 9, naznačen time da je sredstvo za regulaciju proizvodnje trombocita.
12. Kristal etil 3-(4-karboksi-2,6-diklorofenil)-2-metilakrilata naznačen time da ima glavni vršak kod difrakcije X-zraka na prahu s kutom difrakcije 2θ kod 8.1, 16.3, 19.2, 20.0, 24.8, i 39.0 stupnjeva, pri čemu su uvjeti mjerenja difrakcije X-zraka kako slijedi: vakuumska cijev CuK α-zraka, napon rendgenske cijevi 40kV, struja rendgenske cijevi 40mA ili 50mA.
13. Uporaba optički aktivnog spoja predstavljenog s formulom:
[image]
njegova farmaceutski prihvatljiva sol, ili njegov solvat naznačena time da je za proizvodnju medikamenta za regulaciju proizvodnje trombocita.
14. Optički aktivan spoj koji je predstavljen s formulom:
[image]
njegova farmaceutski prihvatljiva sol, ili njegov solvat naznačen time da je za uporabu kod regulaciju proizvodnje trombocita kod sisavca.
15. Uporaba kristala kako je definiran u zahtjevu 6 ili 7 naznačena time da je za proizvodnju medikamenta za regulaciju proizvodnje trombocita.
16. Kristal kako je definiran u zahtjevu 6 ili 7 naznačen time da je za uporabu kod regulacije proizvodnje trombocita kod sisavca.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007198590 | 2007-07-31 | ||
| PCT/JP2008/063541 WO2009017098A1 (ja) | 2007-07-31 | 2008-07-29 | トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体 |
| EP08791776.1A EP2184279B1 (en) | 2007-07-31 | 2008-07-29 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150062T1 true HRP20150062T1 (hr) | 2015-04-10 |
Family
ID=40304328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150062AT HRP20150062T1 (hr) | 2007-07-31 | 2015-01-19 | Farmaceutski pripravak koji sadrži optički aktivan spoj koji sadrži agonist receptora trombopoietina i njegov međuprodukt |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8530668B2 (hr) |
| EP (1) | EP2184279B1 (hr) |
| JP (1) | JP5164181B2 (hr) |
| KR (1) | KR20100027243A (hr) |
| CN (4) | CN101809008B (hr) |
| AU (1) | AU2008283357B2 (hr) |
| BR (1) | BRPI0814891A2 (hr) |
| CA (1) | CA2694567C (hr) |
| CY (1) | CY1116190T1 (hr) |
| DK (1) | DK2184279T3 (hr) |
| ES (1) | ES2528196T3 (hr) |
| FR (1) | FR19C1043I2 (hr) |
| HR (1) | HRP20150062T1 (hr) |
| MX (1) | MX2010001082A (hr) |
| NL (1) | NL300998I2 (hr) |
| PL (1) | PL2184279T3 (hr) |
| PT (1) | PT2184279E (hr) |
| RU (1) | RU2476429C2 (hr) |
| SI (1) | SI2184279T1 (hr) |
| TW (1) | TWI422371B (hr) |
| WO (1) | WO2009017098A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI564008B (zh) * | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
| WO2014003155A1 (ja) * | 2012-06-29 | 2014-01-03 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有する化合物を含有する医薬組成物 |
| US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| CN105992761A (zh) * | 2013-12-20 | 2016-10-05 | 盐野义制药株式会社 | 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法 |
| CN105412930A (zh) * | 2015-08-07 | 2016-03-23 | 军事医学科学院华南干细胞与再生医学研究中心 | 血小板生成素受体激动剂在促进造血干细胞归巢中的用途 |
| JP6168579B1 (ja) * | 2016-02-12 | 2017-07-26 | 塩野義製薬株式会社 | 重度の肝機能障害のある患者のためのルストロンボパグを含有する血小板産生促進剤 |
| CN106083759B (zh) * | 2016-06-15 | 2022-02-15 | 上海丸全化学科技有限公司 | 一种芦曲泊帕的全新合成工艺 |
| WO2018045907A1 (zh) | 2016-09-08 | 2018-03-15 | 四川科伦博泰生物医药股份有限公司 | 一种新型2-酰氨基噻唑衍生物及其制备方法与用途 |
| CN106565625B (zh) * | 2016-11-04 | 2018-01-30 | 杭州励德生物科技有限公司 | 一种抗血小板减少症新药Lusutrombopag中间体的制备方法 |
| WO2018149309A1 (zh) * | 2017-02-14 | 2018-08-23 | 四川科伦药物研究院有限公司 | 4-苯基噻唑衍生物的晶型及其制备方法 |
| CN109970678B (zh) * | 2017-12-28 | 2024-03-08 | 四川科伦药物研究院有限公司 | 4-苯基噻唑衍生物无定形及其制备方法和用途 |
| EP3808736B1 (en) | 2018-06-08 | 2023-08-09 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Crystal form of 4-phenylthiazole derivative and preparation method thereof |
| CN113164455A (zh) * | 2018-12-04 | 2021-07-23 | 盐野义制药株式会社 | 难溶性药物的固体分散体 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL188795B1 (pl) | 1995-06-07 | 2005-04-29 | Glaxo Group Ltd | Związek wiążący się z receptorem trombopoetyny, kompozycja farmaceutyczna i zastosowanie związku wiążącego się z receptorem trombopoetyny |
| JPH1072492A (ja) | 1996-09-02 | 1998-03-17 | Hokuriku Seiyaku Co Ltd | ペプチド化合物 |
| JPH10287634A (ja) | 1997-04-11 | 1998-10-27 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体 |
| JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | １，４−ベンゾジアゼピン誘導体及びその用途 |
| JPH11152276A (ja) | 1997-11-20 | 1999-06-08 | Hokuriku Seiyaku Co Ltd | ベンゾジアゼピン誘導体 |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| CN1376150A (zh) | 1999-07-26 | 2002-10-23 | 盐野义制药株式会社 | 具有血栓形成素受体拮抗作用的药物组合物 |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| EP1354880A4 (en) | 2001-01-26 | 2004-08-25 | Shionogi & Co | HALOGEN COMPOUNDS HAVING AGONISM TOWARDS THROMBOPOIETIN RECEPTOR |
| WO2002059099A1 (fr) | 2001-01-26 | 2002-08-01 | Shionogi & Co., Ltd. | Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine |
| US20040077697A1 (en) | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
| CN1319967C (zh) | 2002-01-18 | 2007-06-06 | 安斯泰来制药有限公司 | 2－酰基氨基噻唑衍生物或其盐 |
| WO2004029049A1 (ja) | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
| US6737382B1 (en) * | 2002-10-23 | 2004-05-18 | Nippon Soda Co. Ltd. | Insecticidal aminothiazole derivatives |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| JP4324791B2 (ja) | 2003-07-17 | 2009-09-02 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| EP1655291B1 (en) * | 2003-08-12 | 2016-08-03 | Shionogi & Co., Ltd. | Compounds having thrombopoietin receptor agonism |
| MXPA06002567A (es) * | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| JP4774995B2 (ja) | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| JP4665769B2 (ja) | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| WO2007004038A1 (en) | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
| US8515798B2 (en) | 2005-09-27 | 2013-08-20 | Accenture Global Services Gmbh | Closed-loop supply chain in the paper packaging sector |
| JP2009514941A (ja) | 2005-11-08 | 2009-04-09 | アステラス製薬株式会社 | 血小板減少症を治療する化合物および方法 |
-
2008
- 2008-07-29 BR BRPI0814891-0A patent/BRPI0814891A2/pt not_active IP Right Cessation
- 2008-07-29 KR KR1020107002144A patent/KR20100027243A/ko active Search and Examination
- 2008-07-29 WO PCT/JP2008/063541 patent/WO2009017098A1/ja active Application Filing
- 2008-07-29 RU RU2010107169/04A patent/RU2476429C2/ru active
- 2008-07-29 ES ES08791776.1T patent/ES2528196T3/es active Active
- 2008-07-29 MX MX2010001082A patent/MX2010001082A/es active IP Right Grant
- 2008-07-29 DK DK08791776.1T patent/DK2184279T3/en active
- 2008-07-29 EP EP08791776.1A patent/EP2184279B1/en active Active
- 2008-07-29 CA CA2694567A patent/CA2694567C/en active Active
- 2008-07-29 US US12/671,476 patent/US8530668B2/en active Active
- 2008-07-29 CN CN2008801104301A patent/CN101809008B/zh active Active
- 2008-07-29 CN CN201310356507.6A patent/CN103450110B/zh active Active
- 2008-07-29 CN CN2013103563691A patent/CN103393678A/zh active Pending
- 2008-07-29 AU AU2008283357A patent/AU2008283357B2/en active Active
- 2008-07-29 PL PL08791776T patent/PL2184279T3/pl unknown
- 2008-07-29 JP JP2009525398A patent/JP5164181B2/ja active Active
- 2008-07-29 CN CN201310356204.4A patent/CN103396313B/zh active Active
- 2008-07-29 SI SI200831361T patent/SI2184279T1/sl unknown
- 2008-07-29 PT PT87917761T patent/PT2184279E/pt unknown
- 2008-07-30 TW TW097128751A patent/TWI422371B/zh active
-
2013
- 2013-02-13 US US13/766,752 patent/US8889722B2/en active Active
-
2015
- 2015-01-19 HR HRP20150062AT patent/HRP20150062T1/hr unknown
- 2015-01-21 CY CY20151100059T patent/CY1116190T1/el unknown
-
2019
- 2019-06-27 NL NL300998C patent/NL300998I2/nl unknown
- 2019-06-28 FR FR19C1043C patent/FR19C1043I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150062T1 (hr) | Farmaceutski pripravak koji sadrži optički aktivan spoj koji sadrži agonist receptora trombopoietina i njegov međuprodukt | |
| DE3884563T2 (de) | Aminomethyl-oxo-oxazolidinyl-ethenylbenzen-Derivate, nützlich als antibakterielles Mittel. | |
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| JP5903162B2 (ja) | 糖尿病の治療に有用な新規１，２，３，４−テトラヒドロキノリン誘導体 | |
| HRP20230931T1 (hr) | Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida | |
| HRP20160355T1 (hr) | Kristalni oblici 4-[5-[3-kloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida | |
| HRP20160208T4 (hr) | Polimorfi dasatiniba i postupak za njihovu pripremu | |
| NZ603594A (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
| JP2016510323A5 (hr) | ||
| PT1888548E (pt) | Derivado de quinolina para o tratamento de doenças da retina | |
| JP2012526123A5 (hr) | ||
| JP2014062126A5 (hr) | ||
| EA018412B1 (ru) | Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20240173T1 (hr) | Fluorofenil beta-hidroksietilamini i njihova upotreba u liječenju hiperglikemije | |
| ME01456B (me) | Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola | |
| HRP20192010T1 (hr) | Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja | |
| BR112012020557A8 (pt) | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio | |
| JP2014533735A (ja) | 外寄生生物を防除するためのアリール誘導体の使用 | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| NZ596820A (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | |
| JP2016539136A5 (hr) | ||
| RU2005122615A (ru) | Соединения n-(индолэтил)циклоамина | |
| JP2010513489A5 (hr) | ||
| CR20210284A (es) | Pirazoles como modulares de hemoglobina |